Company intelligence / Profile preview

ILiAD Biotechnologies

Weston, Florida, United Statesiliadbio.com ↗

Ownership: Private
Employees: ~16
Development stage: Phase 2

Overview

BPZE1 has demonstrated safety, robust mucosal/systemic immune responses, and protection against B. pertussis colonization in four Phase II clinical trials involving adults and school-age children. It showed a significant reduction of nasopharyngeal colonization versus controls in non-human primate studies. The vaccine also demonstrated stability (>2 years at refrigerated temperatures) suitable for global distribution.

Therapeutic areas: ImmunologyNeurologyInfectious Diseases
Modalities: Live attenuated vaccinesVector-based vaccines (B-Tech™ platform)
Industry: Biotech

Drug pipeline

4 assets

BPZE1

3 more assets in the full pipeline.

Partnerships

Licensed BPZE1 technology from Institut Pasteur de Lille & INSERMLetter of intent with hVIVO to conduct pivotal Phase III trial

Beyond the preview

Go deeper on ILiAD Biotechnologies.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ILiAD Biotechnologies.